Clinical trial
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to…
NCT00346073 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00346073 |
|---|---|
| Title | Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years |
| Official title | A Study to Evaluate Immunogenicity and Safety of Boostrix Compared to Adacel When Administered as a Booster Vaccination in Adults Aged 19 to 64 Years of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acellular Pertussis, Diphtheria, Tetanus |
| Intervention type | Biological |
| Interventions | Boostrix™, ADACEL® |
| Enrollment | 2,337 |
| Start date | Jul 13, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 7, 2007 |
| First posted | Jun 29, 2006 |
| Last update posted | Aug 7, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: